TIDMROQ
RNS Number : 8190Q
Roquefort Therapeutics PLC
30 June 2022
30 June 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Results of AGM
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, is pleased to announce that at the Company's Annual General
Meeting ("AGM") held earlier today, all resolutions proposed were
duly passed.
The resolutions were put to shareholders via a poll, the results
of which were as follows:
Poll Results
Resolution For Against Abstain Discretionary Total
----------- -------- -------- -------------- -----------
1 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
2 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
3 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
4 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
5 Shares 15,363,384 35,066 - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.38% 0.21% - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
6 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
7 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
8 Shares 15,398,450 - - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.59% - - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
9 Shares 15,363,384 35,066 - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.38% 0.21% - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
10 Shares 15,363,384 35,066 - 1,600,000 16,998,450
------- ----------- -------- -------- -------------- -----------
% 90.38% 0.21% - 9.41% 100%
------- ----------- -------- -------- -------------- -----------
The total number of ordinary shares in issue on 28 June 2022,
the deadline for casting votes by proxy in advance of the AGM, was
71,900,000 shares. 23.64% of voting capital was instructed in
respect of the resolutions put to the AGM.
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is a pre-clinical
biotech company focused on developing first in class Midkine
targeting drugs for the treatment of cancer.
Through extensive research resulting in validation through
publication in over 1,000 scientific journals, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an
exclusive licence to the largest global IP portfolio on Midkine.
The Midkine blocking drug development markets have significant
global market potential (in the multi-billion dollars). Roquefort
Therapeutic's pre-clinical program is currently underway with an
initial focus on cancer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSDDSUSEESEFM
(END) Dow Jones Newswires
June 30, 2022 05:30 ET (09:30 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jul 2023 to Jul 2024
